{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T13:35:16Z","timestamp":1746192916392},"reference-count":31,"publisher":"Akademiai Kiado Zrt.","issue":"34","license":[{"start":{"date-parts":[[2022,8,21]],"date-time":"2022-08-21T00:00:00Z","timestamp":1661040000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2022,8,21]]},"abstract":"<jats:p>A gl\u00fckokortikoszteroidok a szem\u00e9szeti \u00e9s sziszt\u00e9m\u00e1s gyullad\u00e1sos betegs\u00e9gek\n                    kezel\u00e9s\u00e9ben is kulcsfontoss\u00e1g\u00fa gyullad\u00e1scs\u00f6kkent\u0151k. Hosszan tart\u00f3 alkalmaz\u00e1suk\n                    azonban szemnyom\u00e1s-emelked\u00e9st \u00e9s ennek talaj\u00e1n glaucom\u00e1s neuropathi\u00e1t okozhat,\n                    mely potenci\u00e1lisan ak\u00e1r vaks\u00e1ggal fenyeget\u0151 szem\u00e9szeti sz\u00f6v\u0151dm\u00e9ny. A\n                    szteroidter\u00e1pia nemcsak szem\u00e9szeti k\u00e9sz\u00edtm\u00e9nyek alkalmaz\u00e1sakor emelheti meg a\n                    szemnyom\u00e1st, hanem m\u00e1s alkalmaz\u00e1si m\u00f3dokban is: inhal\u00e1ci\u00f3s, intranasalis,\n                    sziszt\u00e9m\u00e1s. Jelen k\u00f6zlem\u00e9ny\u00fcnk c\u00e9lul t\u0171zte ki, hogy a legfontosabb irodalmi\n                    eredm\u00e9nyek \u00e9s saj\u00e1t klinikai tapasztalataink alapj\u00e1n \u00f6sszefoglal\u00f3 \u00e1ttekint\u00e9st\n                    adjon a szteroidter\u00e1pia induk\u00e1lta iatrog\u00e9n glaucoma etiol\u00f3gi\u00e1j\u00e1r\u00f3l,\n                    diagnosztik\u00e1j\u00e1r\u00f3l \u00e9s kezel\u00e9si lehet\u0151s\u00e9geir\u0151l, r\u00e9szletesen kit\u00e9rve a k\u00fcl\u00f6nb\u00f6z\u0151\n                    kortikoszteroidkezel\u00e9sek alkalmaz\u00e1si m\u00f3djainak \u00f6sszehasonl\u00edt\u00e1s\u00e1ra. A\n                    szteroidter\u00e1pia alkalmaz\u00e1s\u00e1t m\u00e1r kev\u00e9s szakter\u00fcleten lehet elker\u00fclni, ez\u00e9rt\n                    fontos, hogy ahol elny\u00fajtott szteroidter\u00e1pia sz\u00fcks\u00e9ges, minden szakorvosnak\n                    gondolnia kell a szteroidok szemnyom\u00e1semel\u0151 hat\u00e1s\u00e1ra is. A szteroidok\n                    szemnyom\u00e1semel\u0151 hat\u00e1sa f\u00fcgg a hat\u00f3anyag t\u00edpus\u00e1t\u00f3l, a bead\u00e1s m\u00f3dj\u00e1t\u00f3l \u00e9s az\n                    alkalmaz\u00e1s idej\u00e9t\u0151l. Alkalmaz\u00e1si ter\u00fclett\u0151l f\u00fcggetlen\u00fcl rendszeres szem\u00e9szeti\n                    kontroll sz\u00fcks\u00e9ges, k\u00fcl\u00f6n\u00f6s tekintettel a glaucom\u00e1s anamn\u00e9zisre, hisz a tart\u00f3s\n                    szemnyom\u00e1s-emelked\u00e9s a l\u00e1t\u00f3idegrostok visszaford\u00edthatatlan, v\u00e9gs\u0151 soron ak\u00e1r\n                    vaks\u00e1got okoz\u00f3 k\u00e1rosod\u00e1s\u00e1t v\u00e1lthatja ki. A sz\u00f6v\u0151dm\u00e9ny felismer\u00e9s\u00e9nek neh\u00e9zs\u00e9g\u00e9t\n                    fokozza, hogy a szemnyom\u00e1s \u00e1ltal\u00e1ban t\u00fcnet- \u00e9s f\u00e1jdalommentesen emelkedik meg.\n                    Amikor a szteroidter\u00e1pi\u00e1t nem lehet elker\u00fclni, a lehet\u0151 legkev\u00e9sb\u00e9\n                    szemnyom\u00e1semel\u0151 hat\u00f3anyagot a lehet\u0151 legr\u00f6videbb ideig kell v\u00e1lasztani a lehet\u0151\n                    legalacsonyabb d\u00f3zissal. Amennyiben a szemnyom\u00e1s-emelked\u00e9st nem lehet uralni\n                    konzervat\u00edv m\u00f3don, m\u0171t\u00e9ti megold\u00e1s j\u00f6het sz\u00f3ba. Orv Hetil. 2022; 163(34):\n                    1345\u20131352.<\/jats:p>","DOI":"10.1556\/650.2022.32548","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T01:29:26Z","timestamp":1668821366000},"page":"1345-1352","update-policy":"http:\/\/dx.doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":5,"title":["A szteroidter\u00e1pia hat\u00e1sa az intraocularis nyom\u00e1sra"],"prefix":"10.1556","volume":"163","author":[{"given":"Andrea","family":"H\u00e1mor","sequence":"first","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, Szem\u00e9szeti Klinika P\u00e9cs, R\u00e1k\u00f3czi \u00fat 2., 7633 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Mark\u00f3","sequence":"additional","affiliation":[{"name":"Petz Alad\u00e1r Egyetemi Oktat\u00f3 K\u00f3rh\u00e1z Gy\u0151r Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibor","family":"R\u00e1k","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, Szem\u00e9szeti Klinika P\u00e9cs, R\u00e1k\u00f3czi \u00fat 2., 7633 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienne","family":"Csutak","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, Szem\u00e9szeti Klinika P\u00e9cs, R\u00e1k\u00f3czi \u00fat 2., 7633 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/00055735-200012000-00016","article-title":"Ocular complications of topical, peri-ocular, and systemic corticosteroids","volume":"11","author":"Carnahan MC","year":"2000","unstructured":"1 Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol. 2000; 11: 478-483.","journal-title":"Curr Opin Ophthalmol"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2 European Glaucoma Society terminology and guidelines for glaucoma, 4th edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation. Br J Ophthalmol. 2017; 101: 130-195.","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.003"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000309345","article-title":"Corticosteroid glaucoma","volume":"188","author":"3 Fran\u00e7ois","year":"1984","unstructured":"3 Fran\u00e7ois J. Corticosteroid glaucoma. Ophthalmologica 1984; 188: 76-81.","journal-title":"Ophthalmologica"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/sj.eye.6701895","article-title":"Corticosteroid-induced glaucoma: a review of the literature","volume":"20","author":"Kersey JP","year":"2006","unstructured":"4 Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye (Lond). 2006; 20: 407-416.","journal-title":"Eye (Lond)"},{"key":"ref4","unstructured":"5 Feroze KB, Khazaeni L. Steroid induced glaucoma. Last update: March 1, 2022. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL, 2022. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK430685\/ [accessed: January 28, 2022]."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5005\/jp-journals-10028-1226","article-title":"Steroid-induced glaucoma: an avoidable irreversible blindness","volume":"11","author":"6 Phulke","year":"2017","unstructured":"6 Phulke S, Kaushik S, Kaur S, et al. Steroid-induced glaucoma: an avoidable irreversible blindness. J Curr Glaucoma Pract. 2017; 11: 67-72.","journal-title":"J Curr Glaucoma Pract"},{"key":"ref6","unstructured":"7 Armaly MF. Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three levels of response. Invest Ophthalmol. 1965; 4: 187-197."},{"key":"ref7","unstructured":"8 Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol. 1965; 4: 198-205."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2165\/00002512-199915060-00004","article-title":"Corticosteroids and glaucoma risk","volume":"15","author":"9 Tripathi","year":"1999","unstructured":"9 Tripathi RC, Parapuram SK, Tripathi BJ, et al. Corticosteroids and glaucoma risk. Drugs Aging 1999; 15: 439-450.","journal-title":"Drugs Aging"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1089\/jop.1993.9.35","article-title":"Identification of high intraocular pressure responders to topical ophthalmic corticosteroids","volume":"9","author":"10 Bartlett","year":"1993","unstructured":"10 Bartlett JD, Woolley TW, Adams CM. Identification of high intraocular pressure responders to topical ophthalmic corticosteroids. J Ocul Pharmacol. 1993; 9: 35-45.","journal-title":"J Ocul Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/S0140-6736(97)03392-8","article-title":"Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids","volume":"350","author":"11 Garbe","year":"1997","unstructured":"11 Garbe E, LeLorier J, Boivin JF, et al. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet 1997; 350: 979-982.","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/S0161-6420(00)00357-2","article-title":"Ocular hypertensive response to topical dexamethasone in children: a dose-dependent phenomenon","volume":"107","author":"JS","year":"2000","unstructured":"12 Ng JS, Fan DS, Young AL, et al. Ocular hypertensive response to topical dexamethasone in children: a dose-dependent phenomenon. Ophthalmology 2000; 107: 2097-2100.","journal-title":"Ophthalmology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/IJG.0000000000000209","article-title":"Outcome of ocular steroid hypertensive response in children","volume":"25","author":"13 Kaur","year":"2016","unstructured":"13 Kaur S, Dhiman I, Kaushik S, et al. Outcome of ocular steroid hypertensive response in children. J Glaucoma 2016; 25: 343-347.","journal-title":"J Glaucoma"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/0002-9394(75)90687-X","article-title":"Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure","volume":"79","author":"14 Cantrill","year":"1975","unstructured":"14 Cantrill HL, Palmberg PF, Zink HA, et al. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol. 1975; 79: 1012-1017.","journal-title":"Am J Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40266-016-0392-z","article-title":"Clinical applications of dexamethasone for aged eyes","volume":"33","author":"15 Abadia","year":"2016","unstructured":"15 Abadia B, Calvo P, Ferreras A, et al. Clinical applications of dexamethasone for aged eyes. Drugs Aging 2016; 33: 639-646.","journal-title":"Drugs Aging"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1517\/14656566.2014.896899","article-title":"Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant","volume":"15","author":"16 Ciulla","year":"2014","unstructured":"16 Ciulla TA, Harris A, McIntyre N, et al. Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant. Expert Opin Pharmacother. 2014; 15: 953-959.","journal-title":"Expert Opin Pharmacother"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.survophthal.2012.08.003","article-title":"Intraocular pressure monitoring post intravitreal steroids: a systematic review","volume":"58","author":"17 Kiddee","year":"2013","unstructured":"17 Kiddee W, Trope GE, Sheng L, et al. Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol. 2013; 58: 291-310.","journal-title":"Surv Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.ophtha.2013.01.025","article-title":"Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial","volume":"120","author":"18 Friedman","year":"2013","unstructured":"18 Friedman DS, Holbrook JT, Ansari H, et al. Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial. Ophthalmology 2013; 120: 1571-1579.","journal-title":"Ophthalmology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0002-9394(01)01372-1","article-title":"Subtenon's depot corticosteroid injections in patients with a history of corticosteroid-induced intraocular pressure elevation","volume":"133","author":"19 Levin","year":"2002","unstructured":"19 Levin DS, Han DP, Dev S, et al. Subtenon's depot corticosteroid injections in patients with a history of corticosteroid-induced intraocular pressure elevation. Am J Ophthalmol. 2002; 133: 196-202.","journal-title":"Am J Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1001\/jama.1997.03540480029019","article-title":"Glucocorticoid use and risks of ocular hypertension and glaucoma","volume":"277","author":"20 Macris","year":"1997","unstructured":"20 Macris N. Glucocorticoid use and risks of ocular hypertension and glaucoma. JAMA 1997; 277: 1929.","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1016\/S0161-6420(99)90530-4","article-title":"Inhaled corticosteroids, family history, and risk of glaucoma","volume":"106","author":"21 Mitchell","year":"1999","unstructured":"21 Mitchell P, Cumming RG, Mackey DA. Inhaled corticosteroids, family history, and risk of glaucoma. Ophthalmology 1999; 106: 2301-2306.","journal-title":"Ophthalmology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.4168\/aair.2021.13.3.435","article-title":"Inhaled corticosteroid and secondary glaucoma: a meta-analysis of 18 studies","volume":"13","author":"22 Ishii","year":"2021","unstructured":"22 Ishii M, Horita N, Takeuchi M, et al. Inhaled corticosteroid and secondary glaucoma: a meta-analysis of 18 studies. Allergy Asthma Immunol Res. 2021; 13: 435-449.","journal-title":"Allergy Asthma Immunol Res"},{"key":"ref22","unstructured":"23 Nath T, Roy SS, Kumar H, et al. Prevalence of steroid-induced cataract and glaucoma in chronic obstructive pulmonary disease patients attending a tertiary care center in India. Asia Pac J Ophthalmol. 2017; 6: 28-32."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/lary.27209","article-title":"Intranasal corticosteroids do not lead to ocular changes: a systematic review and meta-analysis","volume":"129","author":"24 Valenzuela","year":"2019","unstructured":"24 Valenzuela CV, Liu JC, Vila PM, et al. Intranasal corticosteroids do not lead to ocular changes: a systematic review and meta-analysis. Laryngoscope 2019; 129: 6-12.","journal-title":"Laryngoscope"},{"key":"ref24","unstructured":"25 Weinreb RN, Polansky JW, Kramer SG, et al. Acute effects of dexamethasone on intraocular pressure in glaucoma. Invest Ophthalmol Vis Sci. 1985; 26: 170-175."},{"key":"ref25","unstructured":"26 Guttman Krader C. Risks of steroid use for glaucoma. - Ubiquitous steroid use posing unwitting cause for glaucoma. MedPage Today July 26, 2017. Available from: https:\/\/www.medpagetoday.com\/ophthalmology\/glaucoma\/66879 [accessed: January 28, 2022]."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1001\/archopht.1962.00960030746009","article-title":"Effects of long-term systemic steroids on ocular pressure and tonographic values","volume":"68","author":"Bernstein HN","year":"1962","unstructured":"27 Bernstein HN, Schwartz B. Effects of long-term systemic steroids on ocular pressure and tonographic values. Arch Ophthalmol. 1962; 68: 742-753.","journal-title":"Arch Ophthalmol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1016\/0016-5085(92)90319-T","article-title":"Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure","volume":"102","author":"28 Tripathi","year":"1992","unstructured":"28 Tripathi RC, Kirschner BS, Kipp M, et al. Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure. Gastroenterology 1992; 102: 1957-1961.","journal-title":"Gastroenterology"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000337615","article-title":"Effect of high-dose intravenous methyl-prednisolone treatment on intraocular pressure in multiple sclerosis patients with relapse","volume":"68","author":"29 Acar","year":"2012","unstructured":"29 Acar M, Gedizlioglu M, Koskderelioglu A, et al. Effect of high-dose intravenous methyl-prednisolone treatment on intraocular pressure in multiple sclerosis patients with relapse. Eur Neurol. 2012; 68: 20-22.","journal-title":"Eur Neurol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.survophthal.2020.01.002","article-title":"Steroid-induced glaucoma: epidemiology, pathophysiology, and clinical management","volume":"65","author":"30 Roberti","year":"2020","unstructured":"30 Roberti G, Oddone F, Agnifili L, et al. Steroid-induced glaucoma: epidemiology, pathophysiology, and clinical management. Surv Ophthalmol. 2020; 65: 458-472.","journal-title":"Surv Ophthalmol"},{"key":"ref30","unstructured":"31 Huschle OK, Jonas JB, Koniszewski G, et al. Glaucoma in central hypothalamic-hypophyseal Cushing syndrome. [Glaukom bei zentralem hypothalamisch-hypophys\u00e4rem Cushing-Syndrom]. Fortschr Ophthalmol. 1990; 87: 453-456. [German]"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/163\/34\/article-p1345.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/163\/34\/article-p1345.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/163\/34\/article-p1345.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T15:48:18Z","timestamp":1723132098000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/163\/34\/article-p1345.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,21]]},"references-count":31,"journal-issue":{"issue":"34"},"URL":"https:\/\/doi.org\/10.1556\/650.2022.32548","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"type":"print","value":"0030-6002"},{"type":"electronic","value":"1788-6120"}],"subject":[],"published":{"date-parts":[[2022,8,21]]}}}